financetom
Business
financetom
/
Business
/
ATS Corp Q2 revenue up 18.9%, beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ATS Corp Q2 revenue up 18.9%, beats estimates
Nov 5, 2025 3:40 AM

Overview

* ATS Corp ( ATS ) fiscal Q2 revenue grows 18.9% yr/yr, beating analyst expectations

* Net income for fiscal Q2 was C$33.6 mln, compared to a net loss last year

* Adjusted EPS for fiscal Q2 rose to C$0.45 from C$0.25 a year ago

Outlook

* ATS expects Q3 fiscal 2026 revenue between C$700 mln and C$740 mln

* Company sees strong opportunities in life sciences and energy sectors

* ATS anticipates restructuring expenses of approximately C$15 mln in fiscal 2026

Result Drivers

* ORGANIC GROWTH - Revenue growth driven by 12.6% increase in organic revenues, alongside foreign exchange and acquisitions

* CONSUMER PRODUCTS - Significant revenue increase of 81.5% in consumer products due to higher order backlog

* ENERGY SECTOR - Energy revenues nearly doubled, increasing by 97.7% due to higher order backlog

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat C$728.50 C$723.40

Revenue mln mln (7

Analysts

)

Q2 Net C$33.60

Income mln

Q2 Basic -C$0.34

EPS

Q2 Order C$2.07

Backlog bln

Q2 C$734

Orders mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for ATS Corp ( ATS ) is C$46.00, about 18% above its November 4 closing price of C$37.74

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Flowers Foods CFO Steve Kinsey to Retire at Yearend
Flowers Foods CFO Steve Kinsey to Retire at Yearend
Sep 24, 2025
09:35 AM EDT, 09/24/2025 (MT Newswires) -- Flowers Foods ( FLO ) said Wednesday that Steve Kinsey plans to retire as the company's chief financial officer at the end of the year. The company said it has started a search for its new CFO. Kinsey is expected to remain in an advisory role for a period of time to ensure...
Eight international oil companies reach agreement with Iraq, KRG to resume oil exports
Eight international oil companies reach agreement with Iraq, KRG to resume oil exports
Sep 24, 2025
Sept 24 (Reuters) - The eight international oil companies operating in Iraqi Kurdistan reached agreements in principle with Iraq's federal and Kurdish regional governments to resume oil exports, according to an IOC statement seen by Reuters on Wednesday. The agreed framework, once signed and implemented, will allow exports to restart in the coming days, the statement said. Norway's DNO, and...
Fermi America™ Announces Launch of Initial Public Offering
Fermi America™ Announces Launch of Initial Public Offering
Sep 24, 2025
AMARILLO, Texas, Sept. 24, 2025 /PRNewswire/ -- Fermi LLC (to be converted into Fermi Inc. prior to the effectiveness of its Registration Statement on Form S-11) (Fermi America) announced today that it has launched the roadshow for its proposed initial public offering of 25,000,000 shares of its common stock. In addition, Fermi America intends to grant the underwriters a 30-day...
TG Therapeutics Says 6-Year Briumvi Data Show 90% of Multiple Sclerosis Patients Free From Progression
TG Therapeutics Says 6-Year Briumvi Data Show 90% of Multiple Sclerosis Patients Free From Progression
Sep 24, 2025
09:43 AM EDT, 09/24/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) said Wednesday that new data from phase 3 trials assessing Briumvi showed that 89.9% of relapsing multiple sclerosis patients were free from disability progression during the sixth year of continuous treatment. The company said 10.1% of patients had confirmed disability progression that lasted 24 weeks compared with patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved